Reach out to 
Bryn Pharma Appoints Joshua Ziel as Chief Executive Officer
LEBANON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bryn Pharma, LLC, a privately held pharmaceutical company dedicated to finding a novel and convenient way for patients and caregivers to treat anaphylaxis, today announced that Joshua Ziel, Ph.D., has been appointed Chief Executive Officer (CEO) and member of the Board of Directors. Sandy Loreaux is stepping down as CEO for family-related reasons but will remain on Bryn Pharma’s Board of Directors to continue to help guideBryn Pharma to Present Positive Results from Three New Analyses Further Supporting Use of Its Epinephrine Nasal Spray in Adults at the 2024 AAAAI Annual Meeting
~ Late-breaking presentation demonstrates that a repeat dose of NDS1C epinephrine nasal spray within five minutes safely increases epinephrine absorption by approximately 50 percent compared with a single dose ~ ~ Additionally, new pooled analyses will be presented showing an enhanced...Positive Results from Pivotal Study for Bryn Pharma's Investigational Epinephrine Nasal Spray Published in the Journal of Allergy and Clinical Immunology: Global
~ First study to demonstrate rapid and sustained absorption of NDS1C epinephrine nasal spray compared to epinephrine intramuscular autoinjector, while offering higher and more sustained therapeutic plasma levels ~ ~ Study also found that NDS1C was safe and generally well-tolerated,...Bryn Pharma to Present Positive Clinical Data Supporting Use of Its Epinephrine Nasal Spray in Adults with or without Congestion at 2023 ACAAI Annual Meeting
~ Results showed that NDS1C provides enhanced absorption in adults with or without congestion compared to current first-line intramuscular epinephrine and autoinjector administered treatments ~ ~ The study also found that NDS1C was safe and generally well-tolerated; if approved, NDS1C may...
Read more news
